Featured Press Releases

Shorla Oncology Announces the Launch of Dedicated Sales Force and Market Access Teams as Part of Expansion of Its U.S. Commercial Footprint

Shorla Oncology Announces the Launch of Dedicated Sales Force and Market Access Teams as Part of Expansion of Its U.S. Commercial Footprint

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

Dr. Scott Grady Makes Thyroid RFA More Accessible in Oregon

  • 26 Feb 2025

Dr. Scott Grady, an endocrinologist at Portland Diabetes & Endocrinology Center (PDEC), is making...

Automated red blood cell exchange boosts quality of life for sickle cell patients

Automated red blood cell exchange boosts quality of life for sickle cell patients

Experic appoints Jeffrey Shane as Chief Commercial Officer

Experic appoints Jeffrey Shane as Chief Commercial Officer

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Correction — Privo Technologies

Correction — Privo Technologies

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

  • Sprout Pharmaceuticals
  • 30 Apr 2026
Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

  • YARAL Pharma Inc.
  • 30 Apr 2026
Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

  • SQ Innovation
  • 29 Apr 2026
Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

  • Rapid Nexus
  • 29 Apr 2026
Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

  • Apertura Gene Therapy
  • 28 Apr 2026
AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

  • AbbVie
  • 28 Apr 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.